These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28248151)

  • 1. P2X7 antagonists for CNS indications: recent patent disclosures.
    Pevarello P; Bovolenta S; Tarroni P; Za L; Severi E; Torino D; Vitalone R
    Pharm Pat Anal; 2017 Mar; 6(2):61-76. PubMed ID: 28248151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.
    Chrovian CC; Rech JC; Bhattacharya A; Letavic MA
    Prog Med Chem; 2014; 53():65-100. PubMed ID: 24418608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of P2X7 antagonists with a focus on CNS indications.
    Rech JC; Bhattacharya A; Letavic MA; Savall BM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2X7 receptor antagonists: a patent review (2010-2015).
    Park JH; Kim YC
    Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The P2X7 receptor: A main player in inflammation.
    Adinolfi E; Giuliani AL; De Marchi E; Pegoraro A; Orioli E; Di Virgilio F
    Biochem Pharmacol; 2018 May; 151():234-244. PubMed ID: 29288626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2X7 receptor antagonists for the treatment of systemic inflammatory disorders.
    Gelin CF; Bhattacharya A; Letavic MA
    Prog Med Chem; 2020; 59():63-99. PubMed ID: 32362329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.
    Illes P
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.
    Soni S; Lukhey MS; Thawkar BS; Chintamaneni M; Kaur G; Joshi H; Ramniwas S; Tuli HS
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4643-4656. PubMed ID: 38349395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2X7 receptors in the central nervous system.
    Miras-Portugal MT; Ortega F; Gómez-Villafuertes R; Gualix J; Pérez-Sen R; Delicado EG
    Biochem Pharmacol; 2021 May; 187():114472. PubMed ID: 33587917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
    El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
    Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic P2X receptors: structural models and analysis of ligand-target interaction.
    Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R
    Eur J Med Chem; 2015 Jan; 89():561-80. PubMed ID: 25462266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2X7 receptor: an emerging target in central nervous system diseases.
    Sperlágh B; Illes P
    Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
    Amigoni F; Legnaghi E; Pevarello P
    Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present).
    Iqbal J; Bano S; Khan IA; Huang Q
    Expert Opin Ther Pat; 2024 Apr; 34(4):263-271. PubMed ID: 38828613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
    Scarpellino G; Genova T; Munaron L
    Recent Pat Anticancer Drug Discov; 2019; 14(1):32-38. PubMed ID: 30652649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation.
    Friedle SA; Curet MA; Watters JJ
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):35-45. PubMed ID: 19705995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).
    Celanire S; Sebhat I; Wichmann J; Mayer S; Schann S; Gatti S
    Expert Opin Ther Pat; 2015 Jan; 25(1):69-90. PubMed ID: 25435285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7-NMDA Receptor Antagonists.
    Karoutzou O; Kwak SH; Lee SD; Martínez-Falguera D; Sureda FX; Vázquez S; Kim YC; Barniol-Xicota M
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29361735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody.
    Kaczmarek-Hajek K; Zhang J; Kopp R; Grosche A; Rissiek B; Saul A; Bruzzone S; Engel T; Jooss T; Krautloher A; Schuster S; Magnus T; Stadelmann C; Sirko S; Koch-Nolte F; Eulenburg V; Nicke A
    Elife; 2018 Aug; 7():. PubMed ID: 30074479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The microglial ATP-gated ion channel P2X7 as a CNS drug target.
    Bhattacharya A; Biber K
    Glia; 2016 Oct; 64(10):1772-87. PubMed ID: 27219534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.